Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …

Direct oral anticoagulants (DOACs) that inhibit the coagulation proteases thrombin or factor
Xa (FXa) have replaced warfarin and other vitamin K antagonists (VKAs) for most indications …

within the leg or pelvic veins, and approximately half of all deep-vein thrombi embolize to the
lungs. 1 The annual incidence of pulmonary embolism worldwide is approximately 1 in 1000 …

Background The long‐term risk for recurrent venous thromboembolism (VTE) during
extended anticoagulation for a first unprovoked VTE is uncertain. Objectives To determine …

A state‐of‐the‐art lecture titled “Myeloproliferative Neoplasm‐associated Thrombosis” was
presented at the ISTH congress in 2021. We summarize here the main points of the lecture …

Importance Extending the duration of oral anticoagulation for venous thromboembolism
(VTE) beyond the initial 3 to 6 months of treatment is often recommended, but it is not clear …

Background: Clinical practice guidelines recommend indefinite anticoagulation for a first
unprovoked venous thromboembolism (VTE). Objective: To estimate the benefit–harm …

Deep vein thrombosis (DVT) is the third most common cause of cardiovascular mortality.
Several studies suggest that DVT occurs at the intersection of dysregulated inflammation …

Patients with acute venous thromboembolism (VTE) require anticoagulant therapy to prevent
recurrent VTE and death, which exposes them to an inherent increased risk of bleeding …

Abstract Background and Aims Patients with unprovoked venous thromboembolism (VTE)
have a high recurrence risk, and guidelines suggest extended-phase anticoagulation. Many …